Past, Present and (Possible) Future of CAR-T Cell Therapy Usefully Reviewed by One Nucleus Partners BioIVT
AI-powered drug discovery company Healx opens new labs at Chesterford Research Park
The biotech company secures Suite 3 & 4 in the Science Village
Cambridge, UK, 12th July 2022: Chesterford Research Park is delighted to welcome Healx to the Park’s prestigious Science Village.
Healx, the AI-powered, patient-inspired technology company pioneering the next generation of drug discovery for rare diseases, is taking more than 3,500 sq ft of space within the Park’s multi-occupancy lab building.
The Science Village is home to both established…
A city centre building tailored to the commercialisation of life sciences has reached full capacity. The Biosphere opened its doors just three years ago, and is now home to more than 20 businesses, forming a vibrant and innovative life science cluster on Newcastle Helix.
This fit-for-purpose laboratory and office building is dedicated to life science research, development, and commercialisation. It has become a global hub for innovation, with businesses who are based there working on solutions for some of society’s most pressing global challenges, such as COVID-19, cancer, and climate change…
New Board members will provide expert insight into ADME-Tox, biomarker, assay, cell and gene therapy, and immuno-oncology advances
BioIVT, a leading provider of biospecimens, research models and services for drug and diagnostic development, today announced the launch of its new Scientific Advisory Board (SAB) comprised of experts in ADME-Tox, drug development, cell and gene therapy, immuno-oncology, and clinical diagnostics.
“I am proud to introduce BioIVT’s highly distinguished new SAB members. Our Board members were carefully chosen and are all eminent in their field. They have the skills…
• Stevenage Bioscience Catalyst celebrates its 10th anniversary
• Events focus on the cutting-edge science of our occupier companies
• The campus is now at the heart of the biggest cluster for cell and gene therapy in Europe.
STEVENAGE 11th July 2022: Stevenage Bioscience Catalyst (SBC) is celebrating 10 years since it opened its doors to life sciences companies. A series of events was held on 6th July to celebrate the some of the breakthrough science being undertaken on campus including a science symposium, celebration lunch and scientific poster exhibition.
Dr Sally Ann Forsyth OBE, CEO of…
Innovate UK is offering small and micro businesses a share of up to £30 million in grants alongside tailored business support delivered by Innovate UK EDGE. You can apply for up to £50,000 for highly innovative ideas that have a clear route to commercialisation through business growth.
Your project must lead to new products, processes or services that are significantly ahead of others currently available, or propose an innovative use of existing products, processes or services. It can also involve a new or innovative business model.
In your application, you must be able to show…
RevoluGen Wins 2022 BioNewsRound Award for Translational Research
First Automated Benchtop Fire Monkey HMW-DNA Extraction Installed at Quadram Institute for Pathogen Sequencing and AMR Monitoring
London, UK – 08 July 2022 – UK genomics company, RevoluGen Ltd. (RevoluGen or the Company), is pleased to announce that it has been selected as the winner of the 2022 BioNewsRound Award, for the development and automation of its Fire Monkey High Molecular Weight (HMW) DNA extraction system and successful transfer to its collaborator, Quadram Institute Biosciences (Quadram).
The Award, organised by…
Are you in need a drug delivery system to bring your candidate molecules inside the cell? Are you tired of long and tedious collaborations? Can you imagine being able to arrive at the clinic with your candidate molecule? DIVERSA helps you with your drug delivery challenges.
DIVERSA is a spin-off of the Health Research Institute of Santiago de Compostela (IDIS) and the Servizo Galego de Saúde (SERGAS) established in January 2022. DIVERSA is the exclusive licensee of a new drug delivery technology based on lipid nanoemulsions for small drugs and macromolecules (peptides, proteins, and…
• Further plans for Stevenage campus expansion shared
• Developer partners announced as Reef Group and UBS Asset Management
• GSK to gift land to SBC to enable expansion
STEVENAGE 4th July: Stevenage Bioscience Catalyst (SBC) is based on the life science campus in Stevenage, Hertfordshire. Details of plans to expand the campus were shared today.
The new campus, which will be one of the largest of its kind in the UK and Europe, will be built alongside SBC and its 40+ occupier companies, the Cell and Gene Therapy Catapult and GSK’s existing Global R&D centre. UBS Asset Management and Reef…